These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36769789)

  • 1. Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists.
    Zulkifly HH; Pastori D; Lane DA; Lip GYH
    J Clin Med; 2023 Feb; 12(3):. PubMed ID: 36769789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation.
    Zulkifly H; Cheli P; Lutchman I; Bai Y; Lip GYH; Lane DA
    Thromb Res; 2020 Aug; 192():12-20. PubMed ID: 32416364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention.
    Zulkifly H; Lip GYH; Lane DA
    Int J Clin Pract; 2022; 2022():5951262. PubMed ID: 35685589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.
    Mearns ES; White CM; Kohn CG; Hawthorne J; Song JS; Meng J; Schein JR; Raut MK; Coleman CI
    Thromb J; 2014; 12():14. PubMed ID: 25024644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
    De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
    Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
    Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of Warfarin Anticoagulation in Indigenous and Non-Indigenous Australians With Atrial Fibrillation.
    Nguyen MT; Gallagher C; Pitman BM; Emami M; Kadhim K; Hendriks JM; Middeldorp ME; Roberts-Thomson KC; Mahajan R; Lau DH; Sanders P; Wong CX
    Heart Lung Circ; 2020 Aug; 29(8):1122-1128. PubMed ID: 31980393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation.
    Chan PH; Li WH; Hai JJ; Chan EW; Wong IC; Tse HF; Lip GY; Siu CW
    Can J Cardiol; 2016 Oct; 32(10):1247.e23-1247.e28. PubMed ID: 26927855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists.
    Lobos-Bejarano JM; Castellanos Rodríguez A; Barrios V; Escobar C; Polo-García J; Del Castillo-Rodríguez JC; Vargas-Ortega D; Lopez-Pineda A; Prieto-Valiente L; Lip GYH;
    Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28722795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term oral anticoagulation for atrial fibrillation in low and middle income countries.
    Ramakumar V; Benz AP; Karthikeyan G
    Indian Heart J; 2021; 73(2):244-248. PubMed ID: 33865530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
    Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
    Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project.
    Philippart R; Brunet-Bernard A; Clementy N; Bourguignon T; Mirza A; Angoulvant D; Babuty D; Lip GY; Fauchier L
    Thromb Haemost; 2016 May; 115(5):1056-63. PubMed ID: 26843425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
    Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland.
    Maeder MT; König T; Bogdanovic S; Schneider I; Eugster W; Ammann P; König M; Beer J; Rickli H
    Swiss Med Wkly; 2017; 147():w14503. PubMed ID: 29039622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation.
    Pastori D; Pignatelli P; Saliola M; Carnevale R; Vicario T; Del Ben M; Cangemi R; Barillà F; Lip GY; Violi F
    Int J Cardiol; 2015 Dec; 201():513-6. PubMed ID: 26318513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification.
    Bisson A; Bodin A; Clementy N; Bernard A; Babuty D; Lip GYH; Fauchier L
    Int J Cardiol; 2018 Jun; 260():93-98. PubMed ID: 29540261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study.
    Poli D; Antonucci E; Pengo V; Migliaccio L; Testa S; Lodigiani C; Coffetti N; Facchinetti R; Serricchio G; Falco P; Mangione C; Masottini S; Ruocco L; De Caterina R; Palareti G;
    Int J Cardiol; 2018 Sep; 267():68-73. PubMed ID: 29957264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey.
    Potpara TS; Lip GY; Larsen TB; Madrid A; Dobreanu D; Jędrzejczyk-Patej E; Dagres N;
    Europace; 2016 Oct; 18(10):1593-1598. PubMed ID: 27876696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HIPOGAIA study: Monitoring of oral anticoagulation with vitamin K antagonists in the municipality of Gaia.
    Guedes M; Rego C
    Rev Port Cardiol; 2016 Sep; 35(9):459-65. PubMed ID: 27503590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists.
    Abumuaileq RR; Abu-Assi E; Raposeiras-Roubin S; López-López A; Redondo-Diéguez A; Álvarez-Iglesias D; Rodríguez-Mañero M; Peña-Gil C; González-Juanatey JR
    Europace; 2015 May; 17(5):711-7. PubMed ID: 25662984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.